@ Shanxi people, multiple unit price thousands of yuan drug price reduction!

【Pharmaceutical Network Industry News】The tide of price reduction is coming! Recently, the Shanxi Pharmaceutical and Equipment Center issued a notice on the price reduction of some drugs, involving a total of 22 varieties of 19 enterprises, all of which were actively reduced by
enterprises.

Among the 22 varieties with reduced prices, there are human granulocyte stimulating factor injections, micafine sodium for injection, ibuprofen suspension, memin pseudo-anesthesia oral solution, sodium citrate solution for anticoagulation, bromocriptine mesylate tablets, desmopressin acetate tablets, dinoprostone suppositories, dihydroprelin for injection, hemofiltration replacement base fluid, setipine injection, doxorubicin hydrochloride liposome injection, salmeterol ticasone inhalation powder spray, pravastatin sodium tablets, Compound glycyrrhizinate for injection, etc
.

Among the above varieties, there are many varieties with a unit price of thousands of yuan, including doxorubicin hydrochloride liposome injection, cetepai injection and so on
.

Among them, Fuhe Pharmaceutical's cetepin injection dropped by 20 yuan, from the original 2720 yuan to 2700 yuan; Shanghai Zhangjiang's doxorubicin hydrochloride liposome injection hanging net price is 2329.
41 yuan, and the adjusted net price is 2324.
68 yuan, the decline is relatively small
.

From the perspective of the price of the hanging net, the price reduction is relatively large is the Meimin pseudo-anesthesia oral solution of Tianda Pharmaceutical, and the price has dropped from the original hanging net price of 34.
8 yuan to 18.
46 yuan, a drop of nearly half
.

In addition, Hanyu Pharmaceutical's cabelocetin injection decreased from 173.
17 yuan to 128.
86 yuan, a decrease of about
45 yuan.

In order to reduce the burden of medical expenses on patients and improve the accessibility of drugs, since the beginning of this year, the Shanxi Pharmaceutical and Equipment Center has issued a number of notices of
drug price reductions.

For example, on July 26, the Shanxi Provincial Centralized Bidding and Procurement Network for Pharmaceuticals and Equipment issued the "Notice of Shanxi Province on Adjusting the Online Price of Drugs of 7 Enterprises Including Guangdong East Sunshine Pharmaceutical Co.
, Ltd.
", which shows that according to the application of the enterprise, 9 drugs of 7 enterprises such as Guangdong East Sunshine Pharmaceutical Co.
, Ltd.
were adjusted
.

The overall price adjustment of the hanging net fell by 10%, of which the drug with a relatively large decline was the propofol emulsion injection of North Fresenius Kabi, which fell by 25.
57%, followed by the vascular rehabilitation tablets of Renyuantang Pharmaceutical, with a decrease of 22.
69%.
On June 28, Shanxi Pharmaceutical and Equipment Center issued a document, according to the application of enterprises, Guangzhou Baiyunshan Pharmaceutical Group Co.
, Ltd.
Baiyunshan Pharmaceutical General Factory and other 2 enterprises 39 drug hanging net price adjustment, which involves amoxicillin clavulanate potassium tablets, cefthiamidine for injection, cefazoxime sodium for injection, cefoperazone sodium sulbactam sodium for injection and other varieties
.

Also on the 28th, Shanxi Pharmaceutical And Device Center issued a notice, according to the application of enterprises, Chengdu Diao Jiuhong Pharmaceutical Factory and other 26 enterprises 56 drug hanging net price adjustment, from the list of points of view, many varieties of price reduction is relatively large, For example, the compound blue palm fruit tablets of Chengdu Diao Jiuhong Pharmaceutical Factory dropped from the original 35.
5 yuan to 17.
49 yuan, and the price of many varieties of Haizheng Pharmaceutical was significantly reduced, of which tacrolimus capsules 1mg decreased from 788 yuan to 629 yuan, and tacrolimus capsules 0.
5mg decreased from 466 yuan to 370 yuan
.

Judging from the above documents, all companies have taken the initiative to propose price reductions, which are mainly related to
changes in the pharmaceutical market environment.

The analysis believes that with the promotion of policies such as the normalization of collection and procurement and the control of medical insurance fees, pharmaceutical companies need to make price reduction decisions
in order to obtain local network qualifications or prepare for medical insurance.

Especially in the context of the normalization of collection and procurement, the active price reduction of unselected drugs to obtain local hanging network procurement qualifications is also a common means
adopted by pharmaceutical companies.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.